Drug intelligence / Profile preview

lerzeparib

Development stage: Phase 1
Lead developer: Chia Tai-Tianqing Pharmaceutical Group
Modality: Small Molecules

Overview

**Lerzeparib** is a small molecule **PARP (poly ADP-ribose polymerase) inhibitor** with antineoplastic activity, designed to exploit deficiencies in cancer cells' DNA repair mechanisms by blocking PARP enzymes critical for single-strand break repair. Proposed as an International Nonproprietary Name (INN) in WHO list 129 (August 2023), it carries the '-parib' stem indicative of PARP inhibitors and has the chemical structure 8-fluoro-2-{4-[(2R)-2-methylpyrrolidin-2-yl]phenyl}-1-[(2S)-2-methylpiperidin-1-yl]-1H-benzimidazole-5-carboxamide (CAS 2459693-01-5).[1][3][9][15]

Targets

PARP2 (Poly (adp-ribose) polymerase 2)

Beyond the preview

Go deeper on lerzeparib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on lerzeparib.

Explore the full profile